{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:35:42Z","timestamp":1788338142424,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Sleep Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.5664\/jcsm.10698","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T15:00:31Z","timestamp":1688655631000},"page":"1811-1822","source":"Crossref","is-referenced-by-count":14,"title":["Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia"],"prefix":"10.1007","volume":"19","author":[{"given":"Anne Marie","family":"Morse","sequence":"first","affiliation":[{"name":"Janet Weis Children\u2019s Hospital, Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[{"name":"Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France"},{"name":"University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Arnulf","sequence":"additional","affiliation":[{"name":"Sleep Disorder Unit, Piti\u00e9-Salp\u00eatri\u00e8re Hospital and Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Foldvary-Schaefer","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Chandler","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Chen","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Hickey","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Black","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"},{"name":"Stanford Center for Sleep Sciences and Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Bogan","sequence":"additional","affiliation":[{"name":"University of South Carolina School of Medicine, Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2017.03.009"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101709"},{"key":"e_1_3_3_4_2","volume-title":"International Classification of Sleep Disorders.","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine . International Classification of Sleep Disorders. 3rd ed . Darien, IL : American Academy of Sleep Medicine ; 2014 .","edition":"3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.8.1423"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/30.10.1274"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2020.10.014"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa206"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511093331917"},{"key":"e_1_3_3_10_2","unstructured":"US Food and Drug Administration\n. Clinical review for Binosto NDA 202344. \n2012\n. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202344Orig1s000MedR.pdf\n. Accessed February 28 2023."},{"key":"e_1_3_3_11_2","unstructured":"US Food and Drug Administration\n. Quantitative labeling of sodium potassium and phosphorus for human over-the-counter and prescription drug products. Guidance for industry. \n2022\n. \nhttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug\n. Accessed October 11 2022."},{"key":"e_1_3_3_12_2","volume-title":"Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII","author":"Jazz Pharmaceuticals, Inc","year":"2023","unstructured":"Jazz Pharmaceuticals, Inc . Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]. Palo Alto, CA : Jazz Pharmaceuticals, Inc ; 2023 . https:\/\/pp.jazzpharma.com\/pi\/xywav.en.USPI.pdf . Accessed July 13, 2023."},{"key":"e_1_3_3_13_2","unstructured":"Jazz Pharmaceuticals\n. Jazz Pharmaceuticals announces U.S. FDA approval of Xywav\u00ae (calcium magnesium potassium and sodium oxybates) oral solution for idiopathic hypersomnia in adults [press release]. \n2021\n. \nhttp:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-xywavr-calcium\n. Accessed February 14 2023."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00368-9"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007264"},{"key":"e_1_3_3_16_2","volume-title":"International Classification of Sleep Disorders: Diagnostic & Coding Manual.","author":"American Academy of Sleep Medicine","year":"2005","unstructured":"American Academy of Sleep Medicine . International Classification of Sleep Disorders: Diagnostic & Coding Manual. 2nd ed. Westchester, IL : American Academy of Sleep Medicine ; 2005 .","edition":"2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/32.7.915"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S369122"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9682"},{"key":"e_1_3_3_22_2","unstructured":"Whalen\nM Roy\nB Steininger\nT Dronamraju\nN Enson\nD\n. Patient perspective on idiopathic hypersomnia: impact on quality of life and satisfaction with the diagnostic process and management [abstract]. Presented at: Annual Scientific Meeting of the Associated Professional Sleep Societies; June 4\u20138 2022\n; Charlotte NC."},{"key":"e_1_3_3_23_2","unstructured":"US Bureau of Labor Statistics\n. Household data annual averages. 47. Absences from work of employed full-time wage and salary workers by occupation and industry. \n2022\n. \nhttps:\/\/www.bls.gov\/cps\/cpsaat47.htm\n. Accessed July 14 2022."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2023.101766"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2021.01.018"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12201"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.3480"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.02.009"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2012.07.008"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2014.01.021"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2015.10.005"},{"issue":"1","key":"e_1_3_3_32_2","first-page":"31","article-title":"A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","author":"US Xyrem Multicenter Study Group","year":"2003","unstructured":"US Xyrem Multicenter Study Group . A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy . Sleep. 2003 ; 26 ( 1 ): 31 \u2013 35 .","journal-title":"Sleep."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(18)30133-0"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy128"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-00992-y"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-020-00223-6"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2020.08.034"}],"container-title":["Journal of Clinical Sleep Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:05:00Z","timestamp":1770109500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.5664\/jcsm.10698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.5664\/jcsm.10698"],"URL":"https:\/\/doi.org\/10.5664\/jcsm.10698","relation":{},"ISSN":["1550-9389","1550-9397"],"issn-type":[{"value":"1550-9389","type":"print"},{"value":"1550-9397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}